MedTrace Logo

Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration

NCT02350725 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-06-27

No results posted yet for this study

Summary

The purpose of this pilot study is to investigate the pharmacodynamic and pharmacokinetic parameters of a novel furosemide formulation administered subcutaneously as compared to oral furosemide.

Conditions

Interventions

DRUG

Furosemide injection solution for subcutaneous administration (80 mg)

DRUG

Oral Furosemide tablets (80 mg)

Sponsors & Collaborators

  • scPharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Rudolf A. de Boer, MD, PhD · University Medical Center Groningen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02350725 on ClinicalTrials.gov